ARTICLE | Company News

FDA reviewers say Natpara is effective

September 11, 2014 2:32 AM UTC

NPS Pharmaceuticals Inc. (NASDAQ:NPSP) stock jumped $6.47 (25%) to $32.24 on Wednesday after FDA reviewers concluded that once-daily subcutaneous injections of Natpara reduced the need for calcium and vitamin D supplements in patients with hypoparathyroidism.

In parathyroid hormone 1-84 (PTH) were able to reduce calcium and vitamin D intake by at least 50%. By week 24 of the pivotal REPLACE trial, 43% of Natpara-treated patients achieved independence from vitamin D compared to 5.4% of patients on placebo. ...